ZYDELIG

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, France, Ireland, Italy, Lithuania, Netherlands, New Zealand, Poland, Spain, UK.

Active ingredients

The drug ZYDELIG contains one active pharmaceutical ingredient (API):

1	Idelalisib UNII YG57I8T5M0 - IDELALISIB
	Idelalisib inhibits phosphatidylinositol 3-kinase p110δ (PI3Kδ), which is hyperactive in B-cell malignancies and is central to multiple signalling pathways that drive proliferation, survival, homing, and retention of malignant cells in lymphoid tissues and bone marrow. Idelalisib induces apoptosis and inhibits proliferation in cell lines derived from malignant B-cells and in primary tumour cells.
	Read more about Idelalisib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZYDELIG Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EM01		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
Discover more medicines within L01EM01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11162L, 11165P, 11170X, 11171Y
CA	Health Products and Food Branch	02438798, 02438801
EE	Ravimiamet	1664883, 1664894
ES	Centro de información online de medicamentos de la AEMPS	114938001, 114938002
FR	Base de données publique des médicaments	68093737, 69111017
GB	Medicines & Healthcare Products Regulatory Agency	347180, 347184
IE	Health Products Regulatory Authority	88299, 88333
IT	Agenzia del Farmaco	043620018, 043620020
LT	Valstybinė vaistų kontrolės tarnyba	1074493, 1074494
NL	Z-Index G-Standaard, PRK	120103, 120111
NZ	Medicines and Medical Devices Safety Authority	17527, 17529
PL	Rejestru Produktów Leczniczych	100327258, 100327264
US	FDA, National Drug Code	61958-1701, 61958-1702